These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 26003433)

  • 41. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
    Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
    Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
    Kawakami S; Yasuda S; Ogawa H
    J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
    Hess CN; Peterson ED; Peng SA; de Lemos JA; Fosbol EL; Thomas L; Bhatt DL; Saucedo JF; Wang TY
    J Am Coll Cardiol; 2015 Aug; 66(6):616-27. PubMed ID: 26248987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL; Hansen CL
    Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
    Lee SH; Lee SJ; Heo JH; Ahn SG; Doh JH; Shin S; Shim J; Her AY; Kim BG; Lim SW; Kwon TG; Lee KH; Kim D; Lee YJ; Yu HT; Kim TH; Shin DH; Pak HN; Kim JS
    Am Heart J; 2024 May; 271():48-54. PubMed ID: 38401647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study.
    Schlitt A; Rubboli A; Lip GY; Lahtela H; Valencia J; Karjalainen PP; Weber M; Laine M; Kirchhof P; Niemelä M; Vikman S; Buerke M; Airaksinen KE;
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E864-70. PubMed ID: 23765437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
    Gong X; Hua R; Bai J; Wu T; Wang Q; Zhang J; Zhang W; Ying L; Ke Y; Wang X; Zhang X; Liu K; Chen Y; Zhang B; Dong P; Xiao J; Li C; Zhu L; Li C
    Clin Cardiol; 2023 Jul; 46(7):777-784. PubMed ID: 37191146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
    Liao YWB; Wang TKM
    Coron Artery Dis; 2020 May; 31(3):260-265. PubMed ID: 31821195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry.
    Rubboli A; Schlitt A; Kiviniemi T; Biancari F; Karjalainen PP; Valencia J; Laine M; Kirchhof P; Niemelä M; Vikman S; Lip GY; Airaksinen KE;
    Clin Cardiol; 2014 Jun; 37(6):357-64. PubMed ID: 24481953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
    Eccleston DS; Kim JM; Ten Berg JM; Steg PG; Bhatt DL; Hohnloser SH; de Veer A; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Cannon CP
    Clin Cardiol; 2021 Jul; 44(7):1002-1010. PubMed ID: 34042199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
    Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
    Rubboli A; Saia F; Sciahbasi A; Bacchi-Reggiani ML; Steffanon L; Briguori C; Calabrò P; Palmieri C; Rizzi A; Imperadore F; Sangiorgi GM; Valgimigli M; Carosio G; Steffenino G; Galvani M; Di Pasquale G; La Vecchia L; Maggioni AP; Bolognese L;
    J Invasive Cardiol; 2014 Nov; 26(11):563-9. PubMed ID: 25363997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role.
    Alexopoulos D; Vlachakis P; Lekakis J
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):319-324. PubMed ID: 28643219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).
    Mennuni MG; Halperin JL; Bansilal S; Schoos MM; Theodoropoulos KN; Meelu OA; Sartori S; Giacoppo D; Bernelli C; Moreno PR; Krishnan P; Baber U; Lucarelli C; Dangas GD; Sharma SK; Kini AS; Tamburino C; Chieffo A; Colombo A; Presbitero P; Mehran R
    Am J Cardiol; 2015 Jul; 116(1):37-42. PubMed ID: 25956624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
    Nicolau JC; Bhatt DL; Hohnloser SH; Kimura T; Lip GYH; Miede C; Nordaby M; Oldgren J; Steg PG; Ten Berg JM; Godoy LC; Cannon CP;
    Drugs; 2020 Jul; 80(10):995-1005. PubMed ID: 32562206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
    Fosbol EL; Wang TY; Li S; Piccini J; Lopes RD; Mills RM; Klaskala W; Thomas L; Roe MT; Peterson ED
    Am Heart J; 2013 Nov; 166(5):864-70. PubMed ID: 24176442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention.
    Lu W; Wang Y; Chen L; Li Y; Zhang R; Chen Z; Yan J; Yang M; Han B; Wang Z; He S; Chen L; Wu X; Zeng H; Ma L; Shi G; Yin J; Chen J; Ma G
    Front Cardiovasc Med; 2021; 8():745549. PubMed ID: 34712714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.